The availability of targeted therapies has created a need for precise subtyping of non-small cell lung carcinomas (NSCLCs). The aim of this study was to assess the utility of immunohistochemical markers in subtyping poorly differentiated NSCLC and to compare the results of immunohistochemical staining on biopsies with the corresponding resections. Thirty-nine cases of NSCLC that could not be further classified on biopsy and had subsequent resection specimens were identified. Classification of the tumor was based on the resection specimen using the World Health Organization criteria. All biopsies and resections were stained with CK7, TTF-1, napsin A (novel aspartic proteinase of the pepsin family), p63, CK5/6, and 34βE12. The specimens included 20 adenocarcinomas (ACs), 15 squamous cell carcinomas (SCCs), and 4 large-cell carcinomas (LCCs). TTF-1 was positive in biopsies from 16 of 20 ACs, 2 of 4 LCCs, and none of the SCCs. p63 was positive in all 15 SCCs, 2 of 20 ACs (both were also positive for TTF-1 and napsin A), and none of the LCCs. CK5/6 was positive in 11 of 15 SCCs (all p63 positive) but none of the ACs or LCCs. Napsin A stained 11 of 19 ACs (all TTF-1 positive) but none of the other tumors. Staining for CK7 was present in 19 of 19 ACs and 9 of 15 SCCs. 34βE12 stained both SCCs (15 of 15) and ACs (12 of 20). The combination of TTF-1, napsin A, p63, and CK5/6 allowed an accurate classification of 30 of39 (77%) cases. Of 232 pairs of slides (biopsy and resection) stained with immunohistochemical markers, 12 (5%) showed discrepancies in immunohistochemical staining between biopsies and their corresponding resections. Immunohistochemical staining using a combination of TTF-1, napsin A, p63, and CK5/6 allows subclassification of poorly differentiated NSCLCs on small lung biopsies in most cases. Discrepancies in immunohistochemical staining between biopsies and resections are uncommon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PAS.0b013e3182036d05 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series.
Clin Exp Med
January 2025
Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Lung cancer is one of the major causes of cancer morbidity and mortality. Subtyping of non-small cell lung cancer is necessary owing to different treatment options. This study is to evaluate the value of immunohistochemical expression of glypican-1 in the diagnosis of lung squamous cell carcinoma (SCC).
View Article and Find Full Text PDFPulmonary pleomorphic carcinoma: A rare case showing arterial carcinomatosis mimicking pulmonary artery intimal sarcoma.
Pathol Int
January 2025
Department of Surgical Pathology, Kagoshima University Hospital, Kagoshima, Japan.
A male in his seventies presented with lung cancer in the right lower lobe. The surgically resected specimen revealed a pleomorphic carcinoma featuring an adenocarcinoma component with lepidic, acinar, and papillary patterns, alongside a spindle cell component spreading along the pulmonary artery wall, resembling intimal sarcoma. The spindle tumor cells were positive for keratins, TTF-1, napsin A, and vimentin, but negative for p40, CK14, desmin, alpha-smooth muscle actin, CDK4, and MDM2.
View Article and Find Full Text PDFClinicopathological features and outcomes of rare lung adenocarcinoma metastasis to the thyroid gland: A single-center, 11-year experience.
Thorac Cancer
January 2025
Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- Metastasis of lung adenocarcinoma to the thyroid is uncommon, occurring in 0.1% of cases, and often presents with cough, with most patients showing synchronous tumors and bilateral metastases.
- Diagnosis typically relies on fine-needle aspiration, though misdiagnosis can occur; genetic testing is prevalent and identifies mutations in the epidermal growth factor receptor in more than 70% of patients.
- Treatment approaches are diverse, incorporating surgery, chemotherapy, immunotherapy, and personalized therapies, leading to a median overall survival of 56 months, particularly for those without advanced symptoms.
Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall.
Onco Targets Ther
November 2024
Department of Pathology, Guiqian International Hospital, Guiyang City, Guizhou Province, People's Republic of China.
Background: Mesothelioma is an uncommon malignant tumor with variable clinical presentations, radiological features, and morphological patterns. Mesothelioma with predominantly intrapulmonary growth presents with an insidious onset, similar radiological and even morphological features to lung cancer, and poses a diagnostic pitfall.
Case Presentation: Herein, we reported a 53-year-old female with biphasic mesothelioma misdiagnosed as poorly differentiated adenocarcinoma with focal sarcomatoid carcinoma.
A Case of CUP with Malignant Pleural Effusion: Overcoming Diagnostic and Therapeutic Hurdles with Chemotherapy.
Case Rep Oncol
October 2024
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Article Synopsis
- Cancers of unknown primary (CUPs) pose diagnostic difficulties due to their unidentifiable origins and poor prognosis when associated with massive pleural effusion (MPE).
- A 62-year-old woman with MPE underwent fluid extraction and was diagnosed with adenocarcinoma, raising concerns for gynecological cancer, despite imaging showing no primary malignancy.
- Chemotherapy with carboplatin and paclitaxel improved the patient's performance status and reduced symptoms, suggesting that initial treatment can be effective even in patients with poor health conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!